Abstract
The aim of this study was to assess the association of p53 status with primary cytoreduction, response to chemotherapy and outcome in stage III–IV primary ovarian cancer patients. Immunohistochemical analysis of p53 was performed on formalin-fixed, paraffin-embedded specimens from 168 primary ovarian carcinomas by using the DO-7 monoclonal antibody. p53 nuclear positivity was found in 84 out of 162 (52%) malignant tumours. A higher percentage of p53 nuclear positivity was observed in patients with advanced stage of disease than in stage I–II (57% vs 23% respectively; P = 0.0022) and in poorly differentiated versus well/moderately differentiated tumours (59% vs 32% respectively; P = 0.0038). The multivariate analysis aimed to investigate the association of FIGO stage, grade and p53 status with primary cytoreduction in 136 stage III–IV patients showed that stage IV disease may influence the possibility to perform primary cytoreduction in ovarian cancer patients. p53-positivity also maintained a trend to be associated with poor chance of cytoreduction. In patients who underwent pathologic assessment of response, cases who did not respond to chemotherapy were much more frequently p53-positive than p53-negative (86% vs 14% respectively; P = 0.012). Moreover, patients with stage III disease and < 2-cm residual tumour were more likely to respond to treatment. In multivariate analysis, FIGO stage and p53 expression were independently correlated with pathologic response to chemotherapy. Time to progression and survival rates were shown not to be different in p53-positive versus p53-negative patients.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bodner, SM, Minna, JD, Jensen, SM, D’Amico, D, Carbone, D, Mitsudomi, T, Fedorko, J, Buchhagen, DL, Nau, MM & Gazdar, AF (1992) Expression of mutant p53 proteins in lung cancer correlates with the loss of p53 gene mutation. Oncogene 7: 743–749
Bouvet, M, Ellis, LM, Nishizaki, M, Fijiwara, T, Tiu, W, Bucana, CD, Fang, B, Lee, JJ & Roth, J (1998) Adenovirus-mediated wild-type p53 gene transfer down regulates vascular endothelial growth factor expresion and inhibits angiogenesis in human colon cancer. Cancer Res 58: 2288–2292
Bristow, RE, Lagasse, LD & Karlan, BY (1996) Secondary surgical cytoreduction for advanced epithelial ovarian cancer. Cancer 78: 2049–2062
Brown, R, Clugston, C, Burns, P, Edlin, A, Vasey, P, Kaye, SB & Vojtesek, B (1993) Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer 55: 678–684
Buttitta, F, Marchetti, A, Gadducci, A, Pellegrini, S, Morganti, M, Carnicelli, V, Cosio, S, Gaggetti, O, Genazzani, AR & Bevilacqua, G (1997) p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer 75: 230–235
Cox, DR (1970). Analysis of Binary Data. Methuen: London
Diebold, J, Baretton, G, Felchner, M, Meier, W, Dopfer, K, Schmidt, M & Lohrs, U (1996) Bcl-2 expression, p53 accumulation and apoptosis in ovarian carcinomas. Am J Clin Pathol 105: 341–349
Dong, Y, Walsh, MD, McGuckin, MA, Cummings, MC, Gabrielli, BG, Wright, GR, Hurst, T, Khoo, SK & Parsons, PG (1997) Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer. Int J Cancer 74: 407–414
Eccles, DM, Brett, L, Lessels, A, Gruber, L, Lane, D, Steel, CM & Leonard, RC (1992) Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma. Br J Cancer 65: 40–44
Geisler, JP, Geisler, HE, Wiemann, MC, Givens, SS, Zhou, Z & Miller, GS (1997) Quantification of p53 in epithelial ovarian cancer. Gynecol Oncol 66: 435–438
Gjerset, RA, Turla, ST, Sobol, RE, Scalise, JT, Mercola, D, Collins, M & Hopkins, PJ (1993) Use of wild type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol Carcinog 14: 275–285
Hartmann, LC, Podratz, KC, Keeney, GL, Kamel, NA, Edmonson, JH, Grill, JP, Su, JQ, Katzmann, J & Roche, PC (1994) Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 12: 64–69
Heintz, APM (1996) Surgery in ovarian cancer: the concept of cytoreductive surgery. Curr Opin Obst Gynecol 8: 8–11
Henriksen, R, Strang, P, Wilander, E, Backstrom, T, Tribukait, B & Oberg, K (1994) p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow-cytometry. Gynecol Oncol 53: 301–306
Herod, JJO, Eliopoulos, AG, Warwick, J, Niedobitek, G, Kern, DJ & Young, LS (1996) The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 56: 2178–2184
Katsaros, D, Levesque, M, Genta, F, Durando, A, Arisio, R, Yu, H, Diamandis, EP & Massobrio, M (1998) Prognostic and predictive value of p53 and waf-1 expression in epithelial ovarian cancer. Proc Am Ass Cancer Res 39: (abstract 1355)
Klemi, PJ, Pylkkanen, L, Kiilholma, P, Kurvinen, K & Joensuu, H (1995) p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 76: 1201–1208
Kohler, MF, Kerns, BM, Humphrey, PA, Marks, JR, Bast, RC & Berchuck, A (1993) Mutation and overexpression of p53 in early stage epithelial ovarian cancer. Obstet Gynecol 81: 643–650
Kupryjanczyk, J, Bell, DA, Yandell, DW, Scully, RE & Thor, AD (1994) p53 expression in ovarian borderline tumors and stage I carcinomas. Am J Clin Pathol 102: 671–676
Kupryjanczyk, J, Thor, A, Beauchamp, R, Merritt, V, Edgerton, SM, Bell, DA & Yandell, DW (1993) p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 90: 4961–4965
Levesque, MA, Katsarods, D, Yu, H, Zola, P, Sismondi, P, Giardina, G & Diamandis, EP (1995) Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 75: 1327–1338
Mantel, N (1966) Evaluation of survival data and two new rank order statistics arising its consideration. Cancer Chemother Rep 50: 163–170
Marks, JR, Davidoff, AM, Kerns, BJ, Humphrey, PA, Pence, JC, Dodge, RK, Clarke-Pearson, DL, Iglehart, JD, Bast, RC & Berchuck, A (1991) Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 51: 2979–2984
Marx, D, Meden, H, Ziemek, T, Lenthe, T, Kuhn, W & Schauer, A (1998) Expression of the p53 tumour suppressor gene as prognostic marker in platinum treated patients with ovarian cancer. Eur J Cancer 34: 845–850
Michieli, P, Chedid, M, Lin, D, Pierce, JM, Mercer, WE & Givol, D (1994) Induction of waf1/cip1 by a p53-independent pathway. Cancer Res 54: 3391–3395
Momand, J, Zambetti, GP, Olson, DC, Gorge, D & Levine, HJ (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237–1245
Perego, P, Giarola, M, Righetti, SC, Supino, R, Cesarini, C, Delia, D, Pierotti, MA, Miyashita, T, Reed, JC & Zunino, F (1996) Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56: 556–562
Potter, ME, Partridge, EE, Hatch, KD, Soong, SJ, Austin, JM & Shingleton, HM (1991) Primary surgical therapy of ovarian cancer: how much and when. Gynecol Oncol 40: 195–200
Reles, A, Schmider, A, Press, MF, Schonborn, I, Friedmann, W, Huber-Schumacher, S, Stronmeyer, T & Lintenegger, W (1996) Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome. J Cancer Res Clin Oncol 122: 489–494
Righetti Della Torre, G, Pilotti, S, Menard, S, Ottone, F, Colnaghi, MI, Pierotti, MA, Lavarino, C, Oriana, S, Cornarotti, M, Bohm, S, Bresciani, GC, Spatti, G & Zunino, F (1996) Comparative study of p53 gene mutations, protein accumulation, and response cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 56: 689–693
Rohlke, P, Milde-Langosch, K, Weyland, C, Pichlmeier, U, Janet, W & Loning, T (1997) p53 is a persistent and predictive marker in advanced ovarian carcinomas: multivariate analysis including comparison with Ki67 immunoreactivity. J Cancer Res Clin Oncol 123: 496–501
Scambia, G, Benedetti-Panici, P, Ferrandina, G, Distefano, M, Salerno, G, Romanini, ME, Fagotti, A & Mancuso, S (1995) Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. Br J Cancer 72: 361–366
van der Zee, AGJ, Hollema, H, Suurmeijer, AJH, Krans, M, Sluiter, WJ, Willanse, PH, Alders, JG & de-Vries, EF (1995) Value of p-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 13: 70–78
Werness, BA, Jobe, JS, DiCioccio, A & Pver, S (1997) Expression of the p53 induced tumor suppressor p21waf1/cip1 in ovarian carcinomas: correlation with p53 and Ki-67 immunohistochemistry. Int J Gynecol Pathol 16: 149–155
World Health Organization (1979). WHO Handbook for Reporting Results of Cancer Treatment. WHO: Geneva, pp. 16–21
Author information
Authors and Affiliations
Additional information
Correspondence to:G Scambia
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Ferrandina, G., Fagotti, A., Salerno, M. et al. p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer. Br J Cancer 81, 733–740 (1999). https://doi.org/10.1038/sj.bjc.6690756
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690756
Keywords
This article is cited by
-
Evidence for differential viral oncolytic efficacy in an in vitro model of epithelial ovarian cancer metastasis
Molecular Therapy - Oncolytics (2015)
-
Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review
British Journal of Cancer (2012)
-
TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: A non-randomized retrospective study
BMC Cancer (2008)
-
Prognostic role of topoisomerase-IIα in advanced ovarian cancer patients
British Journal of Cancer (2008)
-
Feasibility evaluation for selection of neoadjuvant chemotherapy before cytoreduction of advanced ovarian carcinoma
Chinese Journal of Clinical Oncology (2007)